http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Catalytic Conversion of Hexagonal Boron Nitride to Graphene for In-Plane Heterostructures
Kim, Gwangwoo,Lim, Hyunseob,Ma, Kyung Yeol,Jang, A-Rang,Ryu, Gyeong Hee,Jung, Minbok,Shin, Hyung-Joon,Lee, Zonghoon,Shin, Hyeon Suk American Chemical Society 2015 NANO LETTERS Vol.15 No.7
<P>Heterostructures of hexagonal boron nitride (h-BN) and graphene have attracted a great deal of attention for potential applications in 2D materials. Although several methods have been developed to produce this material through the partial substitution reaction of graphene, the reverse reaction has not been reported. Though the endothermic nature of this reaction might account for the difficulty and previous absence of such a process, we report herein a new chemical route in which the Pt substrate plays a catalytic role. We propose that this reaction proceeds through h-BN hydrogenation; subsequent graphene growth quickly replaces the initially etched region. Importantly, this conversion reaction enables the controlled formation of patterned in-plane graphene/h-BN heterostructures, without needing the commonly employed protecting mask, simply by using a patterned Pt substrate.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/nalefd/2015/nalefd.2015.15.issue-7/acs.nanolett.5b01704/production/images/medium/nl-2015-017043_0008.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/nl5b01704'>ACS Electronic Supporting Info</A></P>
JooBuom Lee,Kyungsun Lee,Keunbum Choe,Hyunseob Jung,Hyunseok Cho,Kiseok Choi,Taegon Kim,Seojin Kim,Hyeong-Seok Lee,Mi-Jin Cha,Si-Whan Song,Chul Kyu Lee,Gie-Taek Chun 한국독성학회 2015 Toxicological Research Vol.31 No.4
TS-DP2 is a recombinant human granulocyte colony stimulating factor (rhG-CSF) manufactured by TS Corporation. We conducted a four-week study of TS-DP2 (test article) in repeated intravenous doses in male and female Sprague-Dawley (SD) rats. Lenograstim was used as a reference article and was administered intravenously at a dose of 1000 μg/kg/day. Rats received TS-DP2 intravenously at doses of 250, 500, and 1000 μg/kg/day once daily for 4 weeks, and evaluated following a 2-week recovery period. Edema in the hind limbs and loss of mean body weight and body weight gain were observed in both the highest dose group of TS-DP2 and the lenograstim group in male rats. Fibro-osseous lesions were observed in the lenograstim group in both sexes, and at all groups of TS-DP2 in males, and at doses of TS-DP2 500 μg/kg/day and higher in females. The lesion was considered a toxicological change. Therefore, bone is the primary toxicological target of TS-DP2. The lowest observed adverse effect level (LOAEL) in males was 250 μg/kg/day, and no observed adverse effect level (NOAEL) in females was 250 μg/kg/day in this study. In the toxicokinetic study, the serum concentrations of G-CSF were maintained until 8 hr after administration. The systemic exposures (AUC0-24h and C0) were not markedly different between male and female rats, between the administration periods, or between TS-DP2 and lenograstim. In conclusion, TS-DP2 shows toxicological similarity to lenograstim over 4-weeks of repeated doses in rats.
Lee, JooBuom,Lee, Kyungsun,Choe, Keunbum,Jung, Hyunseob,Cho, Hyunseok,Choi, Kiseok,Kim, Taegon,Kim, Seojin,Lee, Hyeong-Seok,Cha, Mi-Jin,Song, Si-Whan,Lee, Chul Kyu,Chun, Gie-Taek Korean Society of ToxicologyKorea Environmental Mu 2015 Toxicological Research Vol.31 No.4
TS-DP2 is a recombinant human granulocyte colony stimulating factor (rhG-CSF) manufactured by TS Corporation. We conducted a four-week study of TS-DP2 (test article) in repeated intravenous doses in male and female Sprague-Dawley (SD) rats. Lenograstim was used as a reference article and was administered intravenously at a dose of $1000{\mu}g/kg/day$. Rats received TS-DP2 intravenously at doses of 250, 500, and $1000{\mu}g/kg/day$ once daily for 4 weeks, and evaluated following a 2-week recovery period. Edema in the hind limbs and loss of mean body weight and body weight gain were observed in both the highest dose group of TS-DP2 and the lenograstim group in male rats. Fibro-osseous lesions were observed in the lenograstim group in both sexes, and at all groups of TS-DP2 in males, and at doses of TS-DP2 $500{\mu}g/kg/day$ and higher in females. The lesion was considered a toxicological change. Therefore, bone is the primary toxicological target of TS-DP2. The lowest observed adverse effect level (LOAEL) in males was $250{\mu}g/kg/day$, and no observed adverse effect level (NOAEL) in females was $250{\mu}g/kg/day$ in this study. In the toxicokinetic study, the serum concentrations of G-CSF were maintained until 8 hr after administration. The systemic exposures ($AUC_{0-24h}$ and $C_0$) were not markedly different between male and female rats, between the administration periods, or between TS-DP2 and lenograstim. In conclusion, TS-DP2 shows toxicological similarity to lenograstim over 4-weeks of repeated doses in rats.
Cesium Lead Halide 페로브스카이트 양자점의 음이온 교환 반응 동역학
이시맥(See Maek Lee),정현성(Hyunsung Jung),박운익(Woonik Park),임현섭(Hyunseob Lim),방지원(Jiwon Bang) 한국표면공학회 2018 한국표면공학회지 Vol.51 No.5
Cesium lead halide perovskite quantum dots (QDs) have recently emerged as highly promising opto-electronic materials. Despite the relative facile anion exchange reactions in cesium lead halide perovskite QDs, in depth study of the anion exchange reactions such as reaction kinetics are required that can provide insight into the crystal transformation in the cesium lead halide perovskite QDs. Herein, we investigated the anion exchange reaction from CsPbI₃ QDs to CsPbBr₃ QDs with varying the particle size of the starting CsPbI₃ QDs. By characterizing the PL spectra in the anion exchange reaction process, we observed that discontinuous PL peak shifts during I-to-Br anion exchange reaction in starting CsPbI₃ QDs over a critical size. Origin of the discontinuous I-to-Br anion exchange kinetics are mainly due to thermodynamically unstable nature of the CsPb(Br/I)₃ alloy QDs.